## **Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

## **Listing of Claims:**

1. (Currently amended) Use of 2-amino-2H-quinazoline derivatives of the general chemical formula I

$$\begin{array}{c|c} R2 & NH_2 \\ \hline R4 & CH_2 & O-R1 \\ \hline R5 & O & (I), \end{array}$$

wherein R1 is an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, as well as their pharmaceutically compatible salts, for producing therapeutic agents for the treatment of myeloproliferative diseases, high blood pressure and for bronchodilation in mammals.

- 2. (Original) The use according to claim 1, further characterized in that at least two residues of R2, R3, R4 and R5 each indicate chlorine atoms.
- 3. (Currently amended) The use according to one of the preceding claims claim 1, further characterized in that R1 stands for methyl or ethyl, R2 and R3 are each hydrogens, and R4 and R5 are each chlorine atoms.

- 4. (Currently amended) The use according to one of the preceding claims claim 1, further characterized in that the pharmaceutically compatible salts are selected from the group comprising the hydrochloride, hydrobromide, sulfate, fumarate, maleate, lactate and succinate.
- 5. (Currently amended) The use according to one of the preceding claims claim 1, further characterized in that the 2-amino-2H-quinazoline derivatives are selected from the group comprising methyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrochloride hemihydrate, methyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrobromide hemihydrate, ethyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrochloride hemihydrate, und ethyl-(2-amino-5,6-dichloro-3,4-dihydro-2H-quinazolin-3-yl) acetate hydrobromide hemihydrate.
- 6. (Currently amended) Use of 2-amino-2H-quinazoline derivatives of the general chemical formula I

$$\begin{array}{c|c} R2 \\ N \\ R4 \\ \hline \\ R5 \\ \hline \end{array} \begin{array}{c} N \\ CH_2 \\ \hline \\ O \\ \hline \end{array} \begin{array}{c} O \\ -R1 \\ \hline \\ O \\ \hline \end{array}$$

wherein R1 indicates an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, and their

pharmaceutically compatible salts, for the treatment of myeloproliferative diseases, high blood pressure and for bronchodilation in mammals.

7. (Currently amended) Use of a pharmaceutical preparation containing at least one agent, selected from the group comprising 2-amino-2H-quinazoline derivatives of the general chemical formula I

$$\begin{array}{c|c}
R2 & NH_2 \\
R4 & CH_2 & CH_2 & O - R1 \\
\hline
R5 & (I),$$

wherein R1 is an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, and their pharmaceutically compatible salts, and at least one pharmaceutically compatible adjuvant, for the treatment of myeloproliferative diseases, high blood pressure and for bronchodilation in mammals.

8. (Original) The use of the pharmaceutical preparation according to claim 7, further characterized in that at least one of the pharmaceutically compatible adjuvants reacts basically in aqueous medium.